Apogee Therapeutics, Inc.
APGE
$82.93
-$1.67-1.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.70% | -40.46% | -72.96% | -100.59% | -98.34% |
| Total Depreciation and Amortization | 341.14% | 650.26% | 862.83% | 1,023.08% | 1,165.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 139.43% | 232.05% | 434.84% | 421.32% | 475.61% |
| Change in Net Operating Assets | -201.87% | -673.13% | -356.01% | -592.90% | -188.78% |
| Cash from Operations | -24.75% | -32.88% | -74.51% | -99.64% | -96.18% |
| Capital Expenditure | 83.78% | -346.79% | -285.15% | -925.48% | -888.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.54% | 41.72% | 141.67% | 99.35% | 29.07% |
| Cash from Investing | 3.32% | 40.23% | 140.21% | 98.12% | 27.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,679.14% | -19.94% | -85.39% | -93.93% | -94.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | 29.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,685.04% | -19.92% | -85.37% | -93.94% | -94.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 191.03% | -144.88% | 83.87% | -200.32% | -209.91% |